← Back to Home

Thyroid Eye Disease Gains an At-Home Injection Option: FDA Approves Enspryng, With Mixed Results Across Two Trials

Maintenance treatment every four weeks could give some patients an opportunity to reduce trips to infusion centers. Beyond convenience, however, one pivotal trial missed its primary endpoint, while comparative efficacy and monitoring at home remain unresolved.

By SURL BioNews

For patients with thyroid eye disease who experience eye bulging and double vision, traveling to a healthcare facility for treatment can itself be a challenge. The U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease, adding an option that patients can inject subcutaneously at home. Genentech announced the approval on October 15, and Roche issued a global announcement the following day. The development brings a change in how treatment is administered, alongside questions about the evidence arising from inconsistent results in two pivotal trials.

Thyroid eye disease is an autoimmune disease affecting the eyes and surrounding tissues. It can cause eye bulging, pain, and double vision and, in severe cases, threaten sight. Enspryng is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), working by inhibiting associated inflammatory signaling. It is also the first IL-6R inhibitor approved in the United States to treat the disease. After training by a healthcare professional, patients or caregivers can administer injections at home, with one injection every four weeks during maintenance treatment.

SatraGO-1 and SatraGO-2, which supported the approval, enrolled a combined 258 patients across 19 countries and compared the drug with placebo. The primary assessment in both Phase III trials was the proportion of patients with active, moderate-to-severe disease whose study eye showed a reduction in proptosis of at least 2 millimeters from baseline at week 24. SatraGO-2 met its primary endpoint, with a response rate of 52.9% in the treatment group and 23.4% in the placebo group. The proportions of patients with active disease who experienced improvement in double vision were 60.7% and 25.8%, respectively.

However, SatraGO-1 did not cross the prespecified statistical threshold. The proptosis response rate in that trial was 49% in the treatment group and 31.2% in the placebo group, a difference that was not statistically significant. Trial investigator César Briceño told *Ophthalmology Times* that the differing statistical outcomes of the two studies may primarily reflect differences in placebo response rates. This is an interpretation of the results and does not eliminate the uncertainty left by one trial's failure to meet its primary endpoint.

Enspryng's place in treatment also cannot be determined simply by lining up numbers from different trials. Briceño believes its degree of improvement in proptosis is smaller than that reported in existing studies of IGF-1R antagonists, but it may still have clinical significance for patients with coexisting conditions and limited options. *Pharmaceutical Executive* also cautioned that no results from direct comparisons with approved therapies have been seen to date. Differences in patient populations and trial designs prevent conclusions about relative efficacy on that basis.

The most immediate benefit of at-home administration is easing the burden of travel and infusion scheduling, particularly for patients who live far from infusion centers and have difficulty driving because of double vision. Roche said the two trials identified no new safety signals, consistent with the drug's established safety profile. This does not mean that treatment at home can dispense with monitoring, however. Clinicians interviewed noted that arranging appropriate follow-up when patients inject themselves remains an issue that must be addressed in clinical use.

The approval was completed through priority review and gives Enspryng a second indication following its 2020 approval for neuromyelitis optica spectrum disorder. However, Roche has not disclosed pricing or a launch timeline for the new indication in its announcement. For patients, approval opens a new avenue for treatment. Whether it can meaningfully reduce the burden of healthcare visits will still depend on access to the drug, costs, and whether treatment at home can be integrated with comprehensive medical care.

References

  1. Roche
  2. Genentech
  3. Ophthalmology Times
  4. Pharmaceutical Executive